Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer Journal Article

  

Authors:	Seidman, A. D.; Scher, H. I.; Petrylak, D.; Dershaw, D. D.; Curley, T.
Article Title:	Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
Abstract:	The combination of estramustine phosphate and vinblastine sulfate, 2 agents with separate and unique antimicrotubular effects, has demonstrated additive cytotoxicity against the DU145 human prostate derived cell line in vitro. We evaluated this combination in 25 patients with progressive hormone refractory prostate cancer. Of 24 patients with an elevated prostate specific antigen (PSA) level at the start of treatment 13 (54%, 95% confidence limits 34 to 74%) had a greater than 50% decrease in PSA levels on at least 3 consecutive biweekly determinations. The median decrease in PSA in responding patients was 64% (mean 71.7%) and the median duration of response was 7 months. In 5 patients with bidimensionally measurable disease 2 partial responses were observed. Treatment was well tolerated, with mild and manageable toxicity. This is a well tolerated outpatient treatment regimen for patients with hormone-refractory prostatic cancer which deserves further investigation.
Keywords:	adult; clinical article; aged; aged, 80 and over; cancer combination chemotherapy; cancer growth; prostate specific antigen; blood toxicity; antineoplastic combined chemotherapy protocols; peripheral neuropathy; tumor markers, biological; cancer pain; cytotoxicity; gonadorelin; vinblastine; cancer hormone therapy; prostate cancer; prostate-specific antigen; prostatic neoplasms; narcotic analgesic agent; antigens, neoplasm; diethylstilbestrol; leukocyte count; flutamide; orchiectomy; gastrointestinal disease; gynecomastia; intravenous drug administration; chlormethine derivative; nitrogen mustard compounds; antigens, differentiation; megestrol acetate; oral drug administration; middle age; megestrol; estramustine; acid phosphatase prostate isoenzyme; human; male; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title:	Journal of Urology
Volume:	147
Issue:	3 Pt. 2
ISSN:	0022-5347
Publisher:	Elsevier Science, Inc.
Date Published:	1992-03-01
Start Page:	931
End Page:	934
Language:	English
PUBMED:	1371564
PROVIDER:	scopus
DOI:	10.1016/s0022-5347(17)37426-8
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026524697&partnerID=40&md5=0cfef415969f832210582190cbde0cdd
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/149929